We performed in vitro and in vivo experiments in order to optimize the anti-tumor activity of our vaccine strategy, using model antigens such as ovalbumin (OVA) as non-self TAA in lymphoma and melanoma models and TRP2 as a self-antigen in the melanoma model. This evidence concerns the gene DCT and melanoma.